Spotlight on Lanreotide Autogel® in Acromegaly

被引：0

作者：

Jamie D. Croxtall

Lesley J. Scott

机构：

[1] Wolters Kluwer Health ¦ Adis,

[2] Wolters Kluwer Health,undefined

来源：

BioDrugs | 2008年 / 22卷

关键词：

Growth Hormone; Acromegaly; Growth Hormone Level; Lanreotide; Somatuline;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Lanreotide Autogel® (ATG) [Somatuline® Depot]1 is a novel, long-acting preparation of the somatostatin analog lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favorable pharmacokinetic profile that permits administration once every 28–42 days.

引用

页码：275 / 277

页数：2

共 50 条

[21] Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland
Stoermann, Sylvere
Schopohl, Jochen
Bullmann, Catharina
Terkamp, Christoph
Christ-Crain, Mirjam
Finke, Reinhard
Flitsch, Joerg
Kreitschmann-Andermahr, Ilonka
Luger, Anton
Stalla, Gunter
Houchard, Aude
Helbig, Dorit
Petersenn, Stephan
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2021, 129 (03) : 224 - 233
[22] Lanreotide for the treatment of acromegaly
F. Castinetti
A. Saveanu
I. Morange
T. Brue
Advances in Therapy, 2009, 26 : 600 - 612
[23] Lanreotide for the treatment of acromegaly
Castinetti, F.
Saveanu, A.
Morange, I.
Brue, T.
ADVANCES IN THERAPY, 2009, 26 (06) : 600 - 612
[24] Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR
Schopohl, J.
Strasburger, C. J.
Caird, D.
Badenhoop, K.
Beuschlein, F.
Droste, M.
Ploeckinger, U.
Petersenn, S.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (03) : 156 - 162
[25] High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Giustina, Andrea
Mazziotti, Gherardo
Cannavo, Salvatore
Castello, Roberto
Arnaldi, Giorgio
Bugari, Giovanna
Cozzi, Renato
Ferone, Diego
Formenti, Anna Maria
Gatti, Enza
Grottoli, Silvia
Maffei, Pietro
Maffezzoni, Filippo
Montini, Marcella
Terzolo, Massimo
Ghigo, Ezio
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (07) : 2454 - 2464
[26] Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
An, Zhenmei
Lei, Ting
Duan, Lian
Hu, Pei
Gou, Zhongping
Zhang, Lihui
Durand-Gasselin, Lucie
Wang, Nan
Wang, Yan
Gu, Feng
BMC ENDOCRINE DISORDERS, 2020, 20 (01)
[27] Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery
Alvarez-Escola, Cristina
Cardenas-Salas, Jersy J.
Pelegrina, Beatriz
Sanz-Valtierra, Angel
Lecumberri, Beatriz
CLINICAL CASE REPORTS, 2015, 3 (11): : 945 - 948
[28] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
Daphne T. Adelman
Dirk Van Genechten
Clémentine M. Megret
Xuan-Mai T. Truong Thanh
Philippa Hand
Wendy A. Martin
Advances in Therapy, 2019, 36 : 3409 - 3423
[29] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
Adelman, Daphne T.
Van Genechten, Dirk
Megret, Clementine M.
Thanh, Xuan-Mai T. Truong
Hand, Philippa
Martin, Wendy A.
ADVANCES IN THERAPY, 2019, 36 (12) : 3409 - 3423
[30] Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
Petersenn, Stephan
Houchard, Aude
Sert, Caroline
Caron, Philippe J.
PITUITARY, 2020, 23 (02) : 171 - 181

← 1 2 3 4 5 →